A Randomized, Double-blind Trial of Lactobacillus GG Versus Placebo in Addition to Standard Maintenance Therapy for Children with Crohnʼs Disease
- 1 September 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 11 (9), 833-839
- https://doi.org/10.1097/01.mib.0000175905.00212.2c
Abstract
Probiotics are widely used by patients with Crohn's disease (CD) in an attempt to improve their health, but few controlled studies have been done to evaluate the efficacy of these therapies. We conducted a randomized, placebo-controlled trial of the probiotic Lactobacillus rhamnosus strain GG (LGG) to see if the addition of LGG to standard therapy prolonged remission in children with CD. Concomitant medications allowed in the study included aminosalicylates, 6-mercaptopurine, azathioprine, and low-dose alternate day corticosteroids. Seventy-five children (age range, 5-21 yr) with CD in remission were randomized to either LGG (n = 39) or placebo (n = 36) and followed for up to 2 years. The median time to relapse was 9.8 months in the LGG group and 11.0 months in the placebo group (P = 0.24); 31% (12/39) of patients in the LGG group developed a relapse compared with 6/36 (17%) of the placebo group (P = 0.18). The LGG was well tolerated, with a side effect profile comparable with placebo. This study suggests that LGG does not prolong time to relapse in children with CD when given as an adjunct to standard therapy.Keywords
This publication has 35 references indexed in Scilit:
- CARD15 gene mutations and risk for early surgery in pediatric-onset Crohn’s diseaseClinical Gastroenterology and Hepatology, 2004
- General principles of medical therapy of inflammatory bowel diseaseGastroenterology Clinics of North America, 2004
- Treatment of inflammatory bowel disease with corticosteroidsGastroenterology Clinics of North America, 2004
- Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's diseaseGastroenterology, 2002
- REVIEW: Role of 5-Aminosalicylic Acid (5-ASA) in Treatment of Inflammatory Bowel Disease: A Systemic ReviewDigestive Diseases and Sciences, 2002
- A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's diseaseGastroenterology, 2000
- Risk factors for low bone mineral density in children and young adults with Crohn’s diseaseThe Journal of Pediatrics, 1999
- EPIDEMIOLOGY AND THE NATURAL COURSE OF INFLAMMATORY BOWEL DISEASEGastroenterology Clinics of North America, 1999
- Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel diseaseGastroenterology, 1998
- The epidemiology of paediatric inflammatory bowel disease.Archives of Disease in Childhood, 1996